CGL
KRTX

Clarius Group LLC’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Clarius Group LLC’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-69,248
Closed -$21.9M – 503
2023
Q4 		$21.9M Sell
69,248
-29,973
-30% -$5.83M 1.82% 12
2023
Q3 		$16.8M Hold
99,221
– – 1.6% 14
2023
Q2 		$21.5M Sell
99,221
-20,475
-17% -$4.39M 1.66% 11
2023
Q1 		$21.7M Buy
119,696
+9,283
+8% +$1.78M 1.85% 11
2022
Q4 		$21.7M Buy
110,413
+447
+0.4% +$95.9K 1.95% 10
2022
Q3 		$24.7M Buy
109,966
+104,514
+1,917% +$21.2M 2.47% 10
2022
Q2 		$690K Buy
+5,452
New +$627K 0.07% 173

Other funds holding KRTX

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

Clarius Group LLC's KRTX Position: Q1 2024 in Review

Clarius Group LLC sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 69,248 shares — an estimated $21.9M sold.

Clarius Group LLC first reported a position in KRTX in Q2 2022 and held it in 7 quarters. The position peaked at $24.7M in Q3 2022. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

  • Clarius Group LLC reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Clarius Group LLC sold 69,248 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $21.9M.
  • Clarius Group LLC first reported a position in Karuna Therapeutics, Inc. Common Stock in Q2 2022 and held it in 7 quarters.
  • Clarius Group LLC's Karuna Therapeutics, Inc. Common Stock position peaked at $24.7M in Q3 2022.
  • 2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Clarius Group LLC's 13F filing for Q1 2024, filed 17 Apr 2024.